MedTrace Logo

Radiofrequency (RF) Ablation Prospective Outcomes Study

NCT04673032 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 298

Last updated 2026-04-15

Study results available
· View outcomes & findings →

Summary

The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems in the treatment of patients diagnosed with pain

Conditions

  • Pain, Chronic

Interventions

DEVICE

Radiofrequency Ablation

Radiofrequency Ablation for treatment of chronic pain

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Natalie Bloom Lyons, M.S. · Boston Scientific Corporation

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-22
Primary Completion
2025-02-07
Completion
2025-02-07
FDA Device
Yes

Countries

  • United States
  • Belgium
  • Italy
  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04673032 on ClinicalTrials.gov